Experimental Biology 2009
          (AAA, APS, ASBMB, ASIP, ASN, ASPET)

    Saturday April 18-Wednesday April 22, 2009
New Orleans, LA

       Abstract Deadline:  November 5, 2008

  ASPET Preliminary Program

Photos courtesy of New Orleans
Convention & Visitors Bureau    

 ASPET Preliminary Program 

Symposia
 

Sunday, April 19

9:30 - 12:00 PM
 

RAY FULLER SYMPOSIUM:  Mechanisms of Nicotine Addiction
Chair:  Henry A. Lester
Convention Center, Room 206
   Preceded by the Ray Fuller Lecture in the Neurosciences

Genome-wide association scans and candidate genes in nicotine addiction.
  Laura S. Bierut, Washington University
Signal transduction pathways in nicotine addiction.
  Darlene Brunzell, Virginia Commonwealth University
Proteasome pathway in nicotine addiction.
  Mariella De Biasi, Baylor College of Medicine
Imaging studies of neural substrates in nicotine addiction.
  Edythe D. London, UCLA

Workshop: Integrating Basic Sciences and Patient Care in a Core Clerkship Curriculum
Chair:  Amy Wilson-Delfosse
Convention Center, Room 208

Integrating basic and clinical sciences in the post-gateway era.
   Frazier Stevenson, UC, Davis
Building integration in a new medical school: University of Central Florida College of Medicine.
   Lynn M. Crespo, University of Central Florida
Integrating basic sciences and patient care in Western Reserve2. 
    Amy L. Wilson-Delfosse,  Case Western Reserve University 
Design of an integrative case:  Small Group Discussions 
    Discussants:  Amy Wilson-Delfosse,  Case Western Reserve University
                         James P. Bruzik, Case Western Reserve University
                         Lynn M. Crespo, University of Central Florida
                         Frazier Stevenson,  UC, Davis
    Small group presentations and panel discussion.

AMPK as a Novel Therapeutic Approach for the Treatment of Metabolic Disorders and Heart Disease
Chairs:  Kenneth B. Walsh and Benoit Viollet
Convention Center, Room 207

Targeting AMPK as a novel therapeutic approach for the treatment of metabolic disorders.
   Benoit Viollet, University of Paris
Cardioprotective effects of adiponectin are mediated in part through AMPK.
   Kenneth Walsh, Boston University School of Medicine
AMPK activation as a strategy for protecting vascular endothelial function.
   Ming-Hui Zou, University of Oklahoma Health Science Center
AMPK activation projects the failing diabetic heart.
   David J. Lefer, Emory University

Advances in Down Syndrome Neuroscience Research:  Implications for Alzheimer's Disease, Dementias and Other Cognitive Disorders
Chairs:  Tim A. Esbenshade and Alberto Costa
Convention Center, Room 210

Advances in Down Syndrome research: Human genetics, animal models and cognitive drug therapy.
  Alberto Costa, University of Colorado Health Sciences Center
Human chromosome 21/Down syndrome gene function: Implications for cognitive development and Alzheimer's Disease. 
  Kathleen Gardiner, University of Denver
Down syndrome: A genetic disorder in biobehavioral perspective.
  Lynn Nadel, University of Arizona
Structural and functional changes at the synapse associated with Down Syndrome and Alzheimer's Disease.
  Craig C. Garner, Stanford University

A Renaissance in Marine Pharmacology:  Preclinical Curiosity to Clinical Reality
Chairs:  Keith B. Glaser and Alejandro M. Mayer
Convention Center, Room 209

Marine-sourced secondary metabolites as leads to drugs.
  David J. Newman, NCI, Frederick
The development of marine anticancer derived compounds in the era of molecular medicine.
  Jose Jimeno, PharmaMar, Madrid
Conus peptides: How snail compounds can win the race.
  J. Michael McIntosh, University of Utah
Harnessing marine natural products for drug discovery: Pragmatic marine microbiology.
  Guy T. Carter, Wyeth Research
The pseudopterosins – Investigation into their mode of action.
  Claudia E. Moya, University of California, Santa Barbara
The global marine pharmacology pipeline: Compounds with anti-infective, immune, anti-inflammatory and CNS activity.
  Alejandro M. Mayer, Midwestern University

Sunday, April 19
3:00 - 5:30 PM

Metabolomics in the Search for Biomarkers for Human Diseases
Chairs:  Frank J. Gonzalez and Richard B. Kim
Convention Center, Room 207

Metabolomics identifies perturbations in human disorders of propionate metabolism.
  William R. Wikoff, The Scripps Research Institute
Metabolite profiling.
  Oliver Fiehn, University of California, Davis
Metabolomics in biomarker discovery: Future uses for cancer prevention.
   Young Kim, NCI, NIH
Metabolomic signatures in the context of systems pathology.
   Jeffrey R. Idle, Charles University, Prague

The Serotonin Transporter:  Not Just for Neurons Anymore
Chair:  A. Elizabeth Linder and Stephanie W. Watts
Convention Center, Room 206

Plasma serotonin levels and the platelet serotonin transporter.
  Fusun Kilic, University of Arkansas for Medical Sciences
5-HT, 5-HT receptors and SERT in the pulmonary circulation.
  Barry L. Fanburg, Tufts University School of Medicine
5-HT uptake in the peripheral vasculature: Focus in veins. 
  A. Elizabeth Linder, Michigan State University
A role for 5-HT in the immune response.
  John Gordon, University of Birmingham, United Kingdom 

Generating Proteomic Diversity in Xenobiotic Biotransformation with Alternative RNA Splicing
Chair:  Curt J. Omiecinski
Convention Center, Room 208

Genome wide analysis and heritability of alternatively spliced transcripts in humans.
   Jacek Majewski, McGill University
Small molecule approaches for dissecting the structure and function of the RNA spliceosome.
   Melissa S. Jurica, UC, Santa Cruz
Correcting aberrant splicing patterns in human disease genes with cell penetrating morpholino oligonucleotides.
   Patrick L. Iverson, AVI Biopharma, Inc.
Aberrant splicing of human P450 genes as a modifier of drug and chemotherapeutic metabolism.
   Ulrich M. Zanger, Dr. Margarete Fischer-Bosch Inst of Clinical Pharmacology, Stuttgart
Alternative splicing of the human xenoreceptor, CAR, results in distinct receptor subtypes with unique biological activities.
   Curt J. Omiecinski, Penn State University

Emerging Approaches to Treatment of Alzheimer’s Disease
Chairs:  Randy Strong and Greg A. Gerhardt
Convention Center, Room 210

Current statue of treatment of Alzheimer’s and related neurodegenerative diseases.
    Randy Strong,  University of Texas Health Science Center Barshop Institute for Longevity & Aging Studies
Understanding angiogenic dysregulation in Alzheimer’s disease: opening the door for new therapeutic strategies in AD. 
   Gregory A. Jicha, University of Kentucky
Pathways of amyloid-beta toxicity:  Potential novel targets for intervention in Alzheimer’s disease.
    Veronica Galvan,  The Buck Institute for Aging Research
The effect of anti-Aß interventions on tau pathology.
   Salvatore Oddo, University of Texas Health Science Center, San Antonio
Estrogen receptor signaling and Alzheimer’s disease.
   Meharvan Singh, University of North Texas Health Science Center, Fort Worth
The future of therapeutics for Alzheimer’s and related diseases.
   Greg Gerhardt, University of Kentucky

Monday, April 20
9:30 - 12:00 PM

JULIUS AXELROD SYMPOSIUM:  The Neurotransmitter End Game: Structure, Function and Regulation of Neurotransmitter Transport 
Chairs:  Randy D. Blakely and Maureen K. Hahn
Convention Center, Room 206
   Preceded by the Julius Axelrod Lecture

The end of cannabinoids as we know it:  Molecular control of anandamide inactivation. 
   Eric L. Barker, Purdue School of Pharmacy
Cocaine (target) trafficking:  Dopamine transporters. 
  Haley E. Melikian, University of Massachusetts Medical School
Hugging Prozac: How serotonin transporters recognize antidepressants.
  L. Keith Henry, University of North Dakota School of Medicine and Health Sciences
Reading the labels: How phosphorylation modifies serotonin transport. 
  Sammanda Ramamoorthy, Medical University of South Carolina
Nothing sweeter than DAT: How insulin controls the dopamine transporter.
  Aurelio Galli, Vanderbilt University

Regenerative Pharmacology:  The New Pharmacology
Chairs:  George J. Christ and Jack W. Strandhoy
Convention Center, Room 209

Introduction:  State of regenerative pharmacology.
    George J. Christ, Wake Forest University Baptist Medical Center
Drug delivery technologies for regenerative pharmacology.
    Grace Lim, Kyunpook National University, Korea
Bio-inductive scaffolds and regenerative nanomaterials for tissue engineering.
    Mark A. Van Dyke, Wake Forest University Baptist Medical Center
Tubular cardiovascular engineering: Developmental pharmacology of muscle, vessel and valves.
   Richard L. Goodwin, University of South Carolina
Regeneration of a complete urinary bladder with an autologous neo-bladder replacement construct - structural, functional and pharmacological characterization.
    Tim Bertram, Tengion, Inc.

MicroRNAs as Biological Effectors and as Pharmacological Targets in the Cardiovascular System
Chair:  J. David Port
Convention Center, Room 207

Role of miR-208 in regulating the expression of myosin heavy chain genes.
   Eva van Rooij, University of Texas Southwestern Medical Center
Correlation between miRNA and mRNA expression in heart failure. 
   J. David Port,  University of Colorado Health Science Center
miRNA regulation of angiotensin receptor expression. 
   Terry Elton, The Ohio State University

The Role of Nuclear Receptors in Lipid Homeostasis
Chair:  Jean-Marc Pascussi and Curt J. Omiecinski
Convention Center, Room 208

Nuclear receptor regulation of bile acid homeostasis. 
   John Chiang, Northeastern Ohio Universities College of Medicine
Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
   Moshe Levi, University of Colorado Health Sciences Center
The nuclear receptor CAR and its role in energy homeostasis.
   Jodi M. Goodwin, Pfizer Global R & D
Crosstalk of CAR and PXR activation as an effector of lipid metabolism and glucose homeostasis.
   Jean-Marc Pascussi, INSERM U632, Montpellier, France

The Role of Insulin and Leptin in Drug Addiction and Mood
Chairs:  Charles P. France and Lynette C. Daws
Convention Center, Room 210

Insulin, leptin, and food reward.
   Dianne P. Figlewicz Lattemann, University of Washington Health Science Center
The role of leptin signaling in emotional behavior.
  Xin-Yun Lu,  University of Texas Health Science Center at San Antonio
DAT depends on what you eat: Neurochemical and behavioral effects of amphetamine are dependent on insulin status.
  Lynette C. Daws, University of Texas Health Science Center at San Antonio
The role of leptin on human body weight regulation, endocrine function, and neurobehavioral outcomes.
  Julio Licinio, University of Miami School of Medicine

Tuesday, April 21
9:30 - 12:00 PM

All Presidents' Symposium on Integrative Pharmacology
Chair:  Dennis C. Marshall and Bill W. Fleming
Convention Center, Room 206

From integrative to molecular pharmacology and back.
   Elaine Sanders-Bush, Vanderbilt University Medical Center
Integrative pharmacology: The validation of biochemical and molecular findings.
   Sam J. Enna, University of Kansas Medical Center
Experimental basis of integrative pharmacology.
   David B. Bylund, University of Nebraska Medical Center
Integrative pharmacological models in understanding neuroplasticity.
   James E. Barrett, Drexel University College of Medicine
Integrative pharmacology:  Oxidative stress, gender and aging.
   Sue P. Duckles, University of California-Irvine, College of Medicine

Exposure to Environmental Agent Alters Epigenetic Homeostasis
Chairs:  Max Costa and Curt J. Omiecinski
Convention Center, Room 208

Epigenetics:  The new genetics of disease susceptibility.
   Randy L. Jirtle, Duke University
Chromatin remodeling by chromium.
   Alvaro Puga, University of Cincinnati
Differentiation of ES cells induced by epigenetic regulation of Pax6.
   Luo Lu, UCLA
Epigenetic effects of nickel exposure.
   Max Costa, New York University School of Medicine
Identifying genome-wide DNA methylation patterns and histone modifications in response to benzo[a]pyrene exposure.
   David I. Rodenhiser, University of Western Ontario

Discovery and Development of Oligonucleotide Therapeutics
Chair:  Tom J. Parry
Convention Center, Room 207

Oligonucleotide therapeutics: Past, present and future.
   James D. Thompson James D. Thompson, Quark Pharmaceuticals, Inc.
Special issues in the discovery and development of RNAi therapeutics.
  Pamela A. Pavco, RXi Pharmaceuticals, Inc., Worcester, MA
Preclinical safety of RNA-based therapeutics. Christina Gamba-Vitalo, Alnylam Pharmaceuticals
Pharmacokinetics of oligonucleotide therapeutics.
   Patrick L. Iversen, AVI BioPharma, Inc.,Corvallis, OR

Targeting Drug Metabolizing Enzymes for Effective Chemopreventive Approaches
Chairs:  Hollie Swanson and Emily E. Scott
Convention Center, Room 209

Inhibitors of cytochrome P45017 alpha as agents for prostate cancer therapy.
   Vincent C. Njar, University of Maryland School of  Medicine
Role of cytochrome P450s in the chemoprevention of tobacco-smoke induced malignancies.
   Stephen S. Hecht, University of Minnesota
Targeting Nrf2, phase I and phase II metabolizing enzymes for effective chemoprevention strategies.
   Ah-Ng Tony Kong, Rutgers University School of Pharmacy
Cytochrome P450 prodrugs in cancer therapy - Targeting tumor cells and tumor-associated endothelial cells.
   David J. Waxman, Boston University

Receptor Signaling and Regulation in Neuropsychiatric Research
Chair: Laura M. Bohn
Convention Center, Room 210

Fine tuning receptor responsiveness.
   Marc G. Caron, Duke University Medical Center
When two receptors become three.
   Lakshmi Devi, Mount Sinai School of Medicine
Serotonin receptor signaling via {beta}-arrestins.
   Laura M. Bohn, Ohio State University College of Medicine
Dopamine receptor signaling via ß-arrestins.
   Martin Beaulieu, University of Laval

Tuesday, April 21
3:00 - 5:30 PM

Neuroplastic and Neurodegenerative Changes Associated with Drug Abuse and Addiction
Chair:  Jean Lud Cadet
Convention Center, Room 210

Transcriptional responses to reinforcing effects of cocaine in the hippocampus and cortex.
   Irina N. Krasnova, NIDA, NIH
Biochemical and molecular consequences of repeated injections of methamphetamine.
   Jean Lud Cadet, NIDA, NIH
Role of microglial activation in drug-induced neurodegeneration.
   Donald M. Kuhn, Wayne State University
Opiates, psychostimulants and adult hippocampal neurogenesis: insight for addiction.
  Amelia Eisch, University of Texas Southwestern Medical Center

Wednesday, April 22
8:00 - 10:30 AM

Virally-encoded G Protein Coupled Receptors as New Drug Targets?
Chair:  Rob Leurs
Convention Center, Room 210

Viral mimicry of G protein coupled receptor signaling.
    Rob Leurs, Vrije University, The Netherlands
HHV-8 encoded GPCR ORF74 and its role in viral oncogenesis.
   J. Silvio Gutkind, NIDCR, NIH
HCMV-encoded GPCR US28 as oncomodulating GPCR.
   Marine J. Smit, Vrije University, The Netherlands
Transgenic mouse models to dissect the role of viral GPCRs in pathogenesis.
  Sergio A. Lira, Mount Sinai School of Medicine
Functional analysis of HCMV-encoded GPCRs using mutant viruses.
  William E. Miller, University of Cincinnati College of Medicine

Therapeutics in Autoimmunity:  Treatment Successes and Side Effects as a Tool of Elucidating Pathogenic Pathways
Chairs:  Carol A. Paronis and Cornelia M. Weyand
Convention Center, Room 207

The making and breaking of the immune system in rheumatoid arthritis - going beyond anti-inflammatory therapy.
  Cornelia M. Weyand, Emory University School of Medicine
Mechanisms of action of methotrexate in rheumatoid arthritis - implications for understanding pathogenic pathways in autoimmunity.
  Bruce N. Cronstein, New York University School of Medicine
Treating autoimmune arthritis through selective tyrosine kinase inhibition.
  William H. Robinson, Stanford University
Pharmacogenomics in rheumatoid arthritis - deciphering disease pathways through better understanding of intended drug effects.
  S. Lou Bridges, University of Alabama at Birmingham

Endothelial Progenitor Cells and Cardiovascular Disease - From Bench to Bedside
Chair:  Alex Chen
Convention Center, Room 208

Oxidative stress and EPC dysfunction in salt-sensitive hypertension
   Alex F. Chen, Michigan State University College of Human Medicine
Role of osteopontin in EPC dysfunction in diabetes mellitus.
  Timothy O’Brien, National University of Ireland
EPC and vascular injury.
  Zvonimir S. Katusic, Mayo Clinic and Foundation
EPC therapies for cardiovascular disease – current perspective.
  Douglas W. Losordo, Northwestern University

Gases as Neuromodulators in Sensing:  From Nitric Oxide to Hydrogen Sulfide
Chair:  Atsufumi Kawabata
Convention Center, Room 206

Neuronal roles for gasotransmitters.
   Phillip K. Moore, King’s College London
Roles for nitric oxide in itching and the development of herpetic and postherpetic neuralgia.
   Yasushi Kuraishi, University of Toyama
Hydrogen sulfide as a neuromodulator in the colon.
   Michael Schemann, Technical University Munich
Hydrogen sulfide and pain
   Atsufumi Kawabata, Kinki University of Pharmacy, Higashi-Osaka

Regulation of Xenobiotic Metabolizing Enzymes in Humans:  Implications for the Propagation of Health and Disease
Chairs:  Charles N. Falany and Melissa Runge-Morris
Convention Center, Room 209

Induction of sulfotransferase (SULT2B1b) expression in cystic fibrosis liver disease.
   Charles N. Falany, University of Alabama at Birmingham
Hepatic sterol metabolism: Regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) by nuclear receptor networks.
   Melissa Runge-Morris, Wayne State University
Genetic polymorphisms in human xenobiotic metabolizing enzymes and cancer risk in steroidogenic tissues.
   Susan A. Nowell Kadlubar, University of Arkansas for Medical Sciences
Genetic polymorphisms affecting xenobiotic metabolism and regulation: Implications for drug therapy and drug-drug interactions in humans.
   Erin G. Schuetz, St. Jude Children’s Research Hospital

Division Sessions

Sunday, April 19
3:00 - 5:30 PM

Pharmacology Education Division Workshop:  Using Human Patient Simulators to Enhance Pharmacology Education Throughout the Undergraduate Medical Curriculum
Chair:  John L. Szarek

Simulation has been a mainstay in graduate medical education, but only recently has it become more common in undergraduate medical education. This workshop will help pharmacology faculty learn how simulation using patient simulators can be used as part of their repertoire of learning modalities for medical students in the first two years and beyond. The workshop will include didactic and hands-on activities on simulation modalities, the rationale for the use of simulation, simulation as a complement to the basic science curriculum, and scenario construction and debriefing.

 Hands on experience using a human patient simulator.
   Facilitators:  John L. Szarek, AT Still University and Robert J. Theobald, Jr., AT Still University, Kirksville, MO

The rationale for the use of simulation as a complement to the basic science curriculum.
  John L. Szarek, AT Still University
Scenario construction and debriefing.
  Susan Pasquale, University of Massachusetts Medical School
Adoption and implementation strategies (and coping strategies for dealing with barriers) that could be used to support using simulation for teaching pharmacology throughout the undergraduate curriculum.
  William B. Jeffries, Creighton University School of Medicine 

Monday, April 20
3:00 - 5:30 PM

Molecular Pharmacology Division Postdoctoral Award Finalists
Chair: Michel Bouvier
Convention Center,  Room 206

Drug Discovery, Development and Regulatory Affairs Division Symposium:  New Insights into Pain Signaling Pathways
Chairs:  Anindya Bhattacharya and Mike F. Jarvis
Convention Center, Room 208

Cannabinoid receptor signaling.
  Kenneth Mackie, Indiana University;
Nav1.7 sodium channels: role in pain mechanisms and targeting by neurotoxins.
  Theodore R. Cummins, Indiana University-Purdue University School of Medicine;
Neuro-glial interactions in pain states:  opportunities for novel drug targets. 
  Joyce A. Deleo, Dartmouth Medical School;
Calcitonin gene-related peptide (CGRP) receptor antagonists for migraine - challenges and promises.
  Stefanie A. Kane, Merck Research Laboratories
GTP cyclohydrolase, tetrahydrobiopterin and pain.
  Michael L. Costigan, Harvard Medical School

 Cardiovascular Pharmacology Division Junior Scientists’ Competition and Benedict R. Lucchesi  Distinguished Award Lecture in Cardiac Pharmacology
 Convention Center, Room 210

Toxicology Division Symposium: The Nrf2-Keap1 System: An Emerging Key Regulator in the Defense Against Oxidative Stress, Chemical Toxicity and Disease
Chair:  Qiang Ma
Convention Center, Room 209

Nrf2: Key to defense against oxidants, electrophiles, radiation and inflammation.
  Paul Talalay, Johns Hopkins School of Medicine
Environmental lung disease and the role of Nrf2.
  Steven R. Kleeberger, NIEHS, NIH, Research Triangle Park, NC
Defense against toxic metals and hyperglycemia by Nrf2.
  Qiang Ma, NIOSH, CDC
Nrf1 and  Nrf2 interplay in regulation of stress response.
  Jefferson Y. Chan, University of California-Irvine, School of Medicine
Keynote Address: Molecular basis for the Nrf2-Keap1 system function.
  Masayuki Yamamoto, Tohoku University School of Medicine, Sendai, Japan

Behavioral Pharmacology Division Symposium: Pharmacological Imaging in Behavioral Pharmacology and Drug Development
Chairs: Leonard L. Howell and Mike A. Nader
Convention Center, Room 207

Pharmacological MRI in awake rats: application for drug discovery and development.
   Chih-Liang Chin, Abbott Laboratories
 Pharmacological MRI studies of the dopaminergic system in rhesus monkeys.
    Zhiming Zhang, University of Kentucky
Functional neuroimaging and cocaine medication development in nonhuman primates.
   Leonard L. Howell, Emory University
PET studies of stimulant drugs in humans.
   Joanna S. Fowler, Brookhaven National Laboratories

Tuesday, April 21
3:00 - 5:30 PM

Clinical Pharmacology, Pharmacogenomics and Translational Pharmacology Division Symposium:  Translational Clinical Pharmacology Research:  Emerging Frontiers
 Chair:  Richard Kim
 Convention Center, Room 207

Delivery of Personalized Medicine:  Examples from the University of Western Ontario.
   Richard B. Kim, University of Western Ontario
In vivo probe drugs for assessing drug interaction potential for drugs in development.
   Joseph W. Polli, GlaxoSmithKline
Drug uptake transporters and cancer therapy:  Bench to bedside. 
   Richard H. Ho, Vanderbilt University

Systems and Integrative Pharmacology Division Young Investigator Platform
Chairs:  David B. Bylund and Dennis C. Marshall
Convention Center, Room 208

Drug Metabolism Division Early Career Achievement Award Lecture and Platform Session
Convention Center, Room 209

Neuropharmacology Division Postdoctoral Scientist Award Finalists
Convention Center, Room 206

Lectures 
 

Sunday, April 19
8:30 - 9:20 AM

RAY FULLER LECTURE IN THE NEUROSCIENCES

Convention Center, Room 206
Lecturer:  Henry A. Lester, Caltech

Changes in the Brain During Chronic Exposure to Nicotine


Sunday, April 19
2:00 - 2:50 PM
 

IUPHAR LECTURE
Convention Center, Room 206

Lecturer:  Robert Lefkowitz, Duke University

  Seven Transmembrane Receptors


 

Monday, April 20
8:30 - 9:20 AM

JULIUS AXELROD AWARD LECTURE
Convention Center, Room 206

 
 Lecturer:  Randy D. Blakely, Vanderbilt University
     Miscarriage at the Synapse:  Brain Disorder-associated Deficits in Membrane    
       Transport
       
   

Monday, April 20
3:00 - 3:50 PM

BENEDICT R. LUCCHESI DISTINGUISHED AWARD LECTURE IN CARDIAC PHARMACOLOGY
Convention Center, Room 210

Tuesday, April 21
8:30 - 9:20 AM

TORALD SOLMANN AWARD LECTURE
Convention Center, Room 206

Special Sessions

Saturday, April 18

2009 Teaching Institute:  Threading New Concepts into Existing Curriculum:  Experiences with Genomics
Chair:  George A. Dunaway
Convention Center, Room 207

Curricular threads in medical school curricula. 
   Phillip R. Musich, East Tennessee State University
Experience with introduction of genomics into medical biochemistry. 
   Phillip R. Musich, East Tennessee State University
Experience with introduction of genomics into medical pharmacology. 
   George A. Dunaway, Southern Illinois University
Development and use of clinical scenarios to introduce pharmacogenomics. 
   George A. Dunaway, Southern Illinois University
Resources for learning and curricular integration of genomics. 
    Phillip R. Musich, East Tennessee State University

Diversity Committee Symposium:  ASPET Travel Fellows:  Lessons Learned Along the Way:
Career Choices from Past Travel Awardees
Chairs:  Gonzalo E. Torres and Dolores Shockley
Convention Center, Room 208

The goal of this symposium is to present and discuss career options taken by past fellows and travel awardees.  The stories are of scientists who made the decision to either stay in academia or leave academic research and forged paths to alternative career options related to science.  These stories will focus on how these scientists got to where they are today and what they have learned along the way.  After the talks, there will be an open session with questions and discussion from the audience.

Career options in science.
    Gonzalo E. Torres, University of Pittsburgh
A career path outside the bench as a medical science liaison. 
  Shola Adewale, Eisia Inc.
Scientific regulatory and policy writing in the government:  Desktop, an alternative to Benchtop. 
   Michelle D. Walker, Drug Enforcement Administration
Career opportunities in biomedical research:  The academic perspective. 
  Chantal A. Rivera,  Louisiana State University Health Sciences Center
Closing remarks
   Dolores C. Shockley,  Meharry Medical College

 Graduate Student-Postdoctoral Colloquium:  Mentoring:  It Goes Both Ways
 Chair:  Sarah H. Lindsey
 Convention Center, Room 209

Entering Mentoring:  Learning to become an effective research mentor
  Chris E. Pfund, University of Wisconsin Program for Scientific Teaching

Tuesday, April 20

 ASPET’s Women in Pharmacology Committee and APS’ Women in Physiology Committee Workshop:  Pathways to Leadership:  Developing Critical Skills 
Chairs:  Andria Lee del Tredici, Holly Brevig, Barbara Alexander
Convention Center, Room 346

Opportunity knocks...(Should I answer?) 
   Kimberly E. Vanover,  Intra-Cellular Therapeutics, Inc.
Surviving hurricane Katrina and embracing new chalenges.
   Patricia Molina, LSU Health Science Center, New Orleans
Pleasures and perils of joint appointments
    Alice M. Young, Texas Tech University Health Science Center
The long and winding road of career development
    Lois D. Lehman-McKeeman, Bristol-Myers Squibb
 

 

Satellite Meetings

FRIDAY & SATURDAY, April 17-18
 

G-Protein Targets Colloquium
Room:  Convention Center 204 A/B/C
(Separate, Advance Registration Required)
Chairs: Alan V. Smrcka and Theresa Filtz

Behavioral Pharmacology Society Meeting
Room:  Convention Center 201
(Separate, Advance Registration Required)
Contact  Nancy Ator: ator@jhmi.edu or 410-550-2773

Public Affairs Session

EB 2008 Public Affairs Session
Monday, April 20
5:00 - 6:30 pm

Evolution of Creationism
(Co-Sponsors: ASPET, ASBMB and APS)
Convention Center, La Louisiane Ballroom
 

Speakers
Chair, Greg Petsko, Brandeis University
Barbara Forrest, Southeastern Louisiana University, author of Creationism’s Trojan Horse
Judge John E. Jones, Federal Judge who presided at the Kitzmiller v. Dover trial in 2005
Ken Miller, Brown University, author of Finding Darwin’s God and other books on the battle over teaching evolution
Eugenie Scott, Executive Director of the National Center for Science Education, Oakland, California, and author of
Evolution versus Creationism (a second edition of which is soon to be published)  

 Public Affairs Symposium: 
Improving NIH Peer Review:  Maintaining the National Strategic Value of Peer Review
Sponsored by APS, AAA, ASPET
Chair:  Tony Scarpa, CSR, NIH

General Information

Awards

Call for Abstracts

Hotels

Registration